Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absorption, Metabolism, and Excretion of [14C]-EP262 in Healthy Males
NCT06645704Phase 1Completed
- Sponsor
- Escient Pharmaceuticals
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of EP262 in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and atopic dermatitis (AD), sponsored by Escient Pharmaceuticals. Primary endpoints: Mass balance of [14C]-EP262 at 1 month and Pharmacokinetics of EP262 and [14C] at 1 month. Started Oct 2024; status: completed.
02
Drugs
EP262
03
Conditions
chronic spontaneous urticaria (CSU)chronic inducible urticaria (CIndU)atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06645704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645704.